Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.
Jason Luke, MD
Advertisement
Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh.
Articles by Jason Luke, MD
Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.
Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.
Jason Luke, MD, Assistant Professor of Medicine, The University of Chicago Medicine, discusses IDO inhibitors in melanoma.
Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5